Novo Nordisk, Neomorph ink $1.46B molecular glue deal
27 Feb 2024
License out/in
Neomorph and Novo Nordisk have announced a collaboration to develop molecular glue degraders targeting cardiometabolic diseases and rare conditions.
The deal, potentially worth $1.46 billion, aims to combine Neomorph's specialized molecular glue discovery platform with Novo Nordisk's expertise in disease management to produce new therapeutic options.
The agreement outlines that Neomorph will handle discovery and preclinical activities, receiving upfront payments, R&D funding, and possible future milestones and royalties, with Novo Nordisk gaining exclusive rights to further clinical development and commercialization.
Founded in 2020, Neomorph focuses on drug discovery against 'undruggable' targets through innovative approaches including protein degradation and molecular glues. Novo Nordisk, known for its diabetes, obesity, and rare blood disorders treatments, seeks to expand its R&D capabilities with this partnership.
The industry has shown a rising interest in molecular glues. Earlier this month, Bristol Myers Squibb teamed with generative AI company VantAI to find new molecular glues for targeted therapeutic purposes.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.